Published in PLoS One on April 04, 2014
The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int J Mol Sci (2014) 1.15
A Review: Proteomics in Nasopharyngeal Carcinoma. Int J Mol Sci (2015) 0.84
Prognostic significance of monocarboxylate transporter expression in oral cavity tumors. Cell Cycle (2016) 0.77
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Recent advances in head and neck cancer. N Engl J Med (2008) 5.05
The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer (1997) 5.01
Profiling early head and neck cancer. Nat Rev Cancer (2005) 2.62
Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev (2007) 2.58
Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res (2005) 2.42
Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci (2007) 2.07
Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol (2010) 1.96
Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. Invest Ophthalmol Vis Sci (2003) 1.83
MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology (2010) 1.82
Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1 complexes with EMMPRIN/basigin/OX47/M6. J Biol Chem (1997) 1.78
Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int (2006) 1.71
Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol (2001) 1.71
Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol (2006) 1.54
Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol (2003) 1.54
Dealing with the family: CD147 interactions with cyclophilins. Immunology (2006) 1.46
EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood (2009) 1.43
The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res (2005) 1.36
Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov (2006) 1.23
Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res (2007) 1.22
Solution characterization of the extracellular region of CD147 and its interaction with its enzyme ligand cyclophilin A. J Mol Biol (2009) 1.21
ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. Mol Cell (2012) 1.21
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer (2008) 1.16
MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol (2010) 1.15
Cathepsin B: a potential prognostic marker for inflammatory breast cancer. J Transl Med (2011) 1.15
EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis (2003) 1.13
Basigin-2 is a cell surface receptor for soluble basigin ligand. J Biol Chem (2008) 1.13
Female sterility in mice lacking the basigin gene, which encodes a transmembrane glycoprotein belonging to the immunoglobulin superfamily. FEBS Lett (1998) 1.12
Roles of basigin, a member of the immunoglobulin superfamily, in behavior as to an irritating odor, lymphocyte response, and blood-brain barrier. Biochem Biophys Res Commun (1996) 1.07
Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Res (2011) 1.07
The LG1-3 tandem of laminin alpha5 harbors the binding sites of Lutheran/basal cell adhesion molecule and alpha3beta1/alpha6beta1 integrins. J Biol Chem (2007) 1.04
Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study. Mol Cancer (2010) 1.03
Direct cell-cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblasts: involvement of EMMPRIN and MT1-MMP. Exp Cell Res (2004) 1.01
Characterization of basigin isoforms and the inhibitory function of basigin-3 in human hepatocellular carcinoma proliferation and invasion. Mol Cell Biol (2011) 0.99
Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B. Int J Cancer (2012) 0.96
Unavailability of CD147 leads to selective erythrocyte trapping in the spleen. Blood (2001) 0.95
A novel form of the membrane protein CD147 that contains an extra Ig-like domain and interacts homophilically. BMC Biochem (2003) 0.94
EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. Int J Cancer (2006) 0.92
EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pancreatobiliary adenocarcinoma in Chinese people. APMIS (2007) 0.90
Targeting Id1 reduces proliferation and invasion in aggressive human salivary gland cancer cells. BMC Cancer (2013) 0.85
EMMPRIN expression in tongue squamous cell carcinoma. J Oral Pathol Med (2009) 0.85
EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression. BMC Cancer (2012) 0.85
EMMPRIN modulates migration and deposition of TN-C in oral squamous carcinoma. Anticancer Res (2008) 0.83
Role of neurofilament light polypeptide in head and neck cancer chemoresistance. Mol Cancer Res (2012) 0.83
In vitro effects of nitric oxide synthase inhibitor L-NAME on oral squamous cell carcinoma: a preliminary study. Int J Oral Maxillofac Surg (2006) 0.82
The role of antiangiogenic agents in the treatment of head and neck cancer. Oncology (2012) 0.78
Extracellular matrix metalloproteinase inducer expression in salivary gland tumors: a correlation with microvessel density. J Craniofac Surg (2010) 0.76